

Express Mail Label No.: EV 392131232 US
Date of Deposit: July 26, 2004



07-28.04

IFW

Attorney Docket No.: 25720-502

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Francois Spertini
SERIAL NUMBER: 10/799,514 EXAMINER : Not Yet Assigned
FILING DATE: March 12, 2004 ART UNIT : 1644
FOR: ALLERGEN PEPTIDE FRAGMENTS AND USE THEREOF

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Copies of Cited References: C16- 24; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 25720-502. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Matthew Puro Reg No. 59572
L.

Ivor R. Elrifi, Reg. No. 39,529
Attorney(s) for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.

Address all written correspondence to


Customer no.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

Date: July 26, 2004

Express Mail Label No.: EV 392131232 US
Date of Deposit: July 26, 2004



Attorney Docket No.: 25720-502

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Francois Spertini
SERIAL NUMBER: 10/799,514 EXAMINER : Not Yet Assigned
FILING DATE: March 12, 2004 ART UNIT : 1644
FOR: ALLERGEN PEPTIDE FRAGMENTS AND USE THEREOF

MAIL STOP AMENDMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

· APPLICANT: Francois Spertini
U.S.S.N.: 10/799,514

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 25720-502.

Respectfully submitted,

Matthew Pano Reg. No. 50,529
f: Ivor R. Elrifi, Reg. No. 39,529

Attorney(s) for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer no.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

Date: July 26, 2004

TRA 1942770v1



Please type a plus sign (+) in this box



Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/799,514
	Filing Date	March 12, 2004
	First Named Inventor	Speritini
	Group Art Unit	1644
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	25720-502

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)		Date of Publication	Translation Yes No	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C16	Astori, et al., <i>J. Immunol.</i> , 165:3497-3505 (2000).
	C17	Fellarth, et al., <i>J. Allergy Clin. Immunol.</i> , 111:854-861 (2003).
	C18	Jilek, et al., <i>J. Immunol.</i> , 166:3612-3621 (2001).
	C19	Kettner, et al., <i>J. Allergy Clin. Immunol.</i> , 107:914-920 (2001).
	C20	Speritini, et al., Abstract Basel presented at the Swiss Society for Immunology, Basel, April 6-7 2000, and published in <i>Allergologie</i> , 23/3. 2000, p.156.
	C21	Speritini, et al., Abstract Berlin presented at EAACI (Eur. Acad. Allergy Clin. Immunol.) Congress, Berlin, May 9-13 2001, and published in <i>Allergy</i> , 56(suppl. 68):38.
	C22	Speritini, et al., Abstract ICACI Sydney presented at the XVII ICACI (Int. Congress Allergol. Clin. Immunol.) Sydney, Aus., 15-20 October, 2000, and published in <i>Allergy and Clin. Immunol. Int.</i>
	C23	Speritini, et al., Abstract AAAI presented at AAAAI (Am. Acad. Allergy Asthma and Immunol.) San Diego, March 3-8, 2000, and published in <i>J. Allergy Clin. Immunol.</i> , 105(1 – pt. 2):S278.
	C24	Von Garnier, et al., <i>Eur. J. Immunol.</i> , 30:1638-1645 (2000).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.